Orum Therapeutics Presents Positive Preclinical Data Of ORM-6151 at ASH 2022

Dec 10

Written By Sophia (Sujin) Kim

Title: ORM-6151, A First-In-Class, CD33-GSPT1 Dual-Precision Targeted Protein Degrader For AML.

Date and Time: 12/10/22 5:30 PM to 7:30 PM CST

Sophia (Sujin) Kim

Orum Therapeutics Announces Three Presentations At AACR 2023

Orum Therapeutics Presents Positive Preclinical Data Of ORM-6151, A First-In-Class, CD33-GSPT1 Dual-Precision Targeted Protein Degrader For AML, At ASH 2022